200 related articles for article (PubMed ID: 22167408)
1. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
Jamal-Hanjani M; Spicer J
Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
[TBL] [Abstract][Full Text] [Related]
2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
3. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Bartolotti M; Franceschi E; Brandes AA
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
[TBL] [Abstract][Full Text] [Related]
4. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
6. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
8. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
Kotsakis A; Georgoulias V
Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
[TBL] [Abstract][Full Text] [Related]
10. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Pan M; Santamaria M; Wollman DB
Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
[TBL] [Abstract][Full Text] [Related]
11. Brain metastasis responding to gefitinib alone.
Poon AN; Ho SS; Yeo W; Mok TS
Oncology; 2004; 67(2):174-8. PubMed ID: 15539923
[TBL] [Abstract][Full Text] [Related]
12. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Fang L; Sun X; Song Y; Zhang Y; Li F; Xu Y; Ma S; Lin N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):873-7. PubMed ID: 26310285
[TBL] [Abstract][Full Text] [Related]
13. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Kuiper JL; Smit EF
Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Chen Y; Wang M; Zhong W; Zhao J
Lung Cancer; 2013 Nov; 82(2):313-8. PubMed ID: 24011632
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
16. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
[No Abstract] [Full Text] [Related]
17. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Togashi Y; Masago K; Fukudo M; Terada T; Fujita S; Irisa K; Sakamori Y; Kim YH; Mio T; Inui K; Mishima M
J Thorac Oncol; 2010 Jul; 5(7):950-5. PubMed ID: 20479691
[TBL] [Abstract][Full Text] [Related]
19. Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Liu SF; Huang KT; Chen HC; Chang YC; Lin MC
PLoS One; 2016; 11(2):e0149722. PubMed ID: 26894507
[TBL] [Abstract][Full Text] [Related]
20. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Sekine A; Satoh H
Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
